FDA has recently approved first ever novel migraine preventive drug that resorts to prevention rather than treatment. It is posed as a breakthrough drug with immense market potential in upcoming years. The report ?Global Migraine Market (By Nations-The US, the UK, Germany, France, Italy, Spain and Japan; Drugs- Triptan, CGRP, Others) - Outlook 2024? provides information on the current scenario, detailed market outlook of the global migraine treatment market with detailed analysis of major drug classes such as Triptan, CGRP and other drug classes. The market is further analysed with detailed market outlook for global as well as regional markets such as North America, Europe and Asia Pacific. The analysis is provided for all the major market across the world such as The US, Germany, France, The UK, Spain, Italy and Japan. Market outlook for overall market as well as for various segments for aforementioned regions has been provided for the period 2018-24.
The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in global migraine treatment market. The report has been segmented as following:-
Drug Classes
? Triptan
? CGRP
? Others
Geographical Coverage
? North America - The US
? Europe - Germany, The UK, Italy, Spain & France
? Asia Pacific - Japan
Companies Coverage
? Eli Lilly & Company
? Teva Pharmaceutical Industries
? Alder Biopharmaceuticals
? Amgen Inc.

Migraine is a complex debilitating disorder. It is a form of recurrent headaches often characterized by intense pulsating pain in one side of the head. It is one of the most common disorders of the nervous system. There are various migraine treatment options available in the market depending on the frequency and severity of headaches, the degree of disability caused, and other medical conditions. These treatment options range from conventional medicines to supplements, herbs and various others. Conventional medicine for migraine treatment can be broadly divided into three categories - Abortive, Preventive and Complementary. Some of the common migraine drug classes include Triptan, Calcitonin Gene Related Peptide (CGRP), Tezampanel and Ergots Alkaloids. Triptan dominates acute migraine treatment market.
Global migraine drugs market has been relatively stagnant over past several years. Growth of the industry is attributed to increasing incidences of migraine cases and patent expirations. Rising female population also positively impacts the market as migraine is said to be one of the most common disorders affecting women. However, some of the factors restraining growth of the industry are poor efficacy of drugs, regulatory hurdles and low diagnosis rate of migraine.
The report ?Global Migraine Market (By Nations-The US, the UK, Germany, France, Italy, Spain and Japan; Drugs- Triptan, CGRP, Others) - Outlook 2024? provides information on the current scenario, detailed market outlook of the global migraine treatment market with detailed analysis of major drug classes such as Triptan, CGRP and other drug classes. The market is further analysed with detailed market outlook for global as well as regional markets such as North America, Europe and Asia Pacific. The analysis is provided for all the major market across the world such as The US, Germany, France, The UK, Spain, Italy and Japan. Future forecasts of Migraine treatment market overall and across various sub-segments has been provided till 2024, for all the geographies and all the drug classes. Furthermore, major industry players have been prudently analysed in the competitive landscape section of the report in order to provide key comparative insights.
Major industry players operating in the market includes Eli Lilly & Company, Teva Pharmaceutical Industries, Alder Biopharmaceuticals and Amgen Inc. These players are profiled herein based on attributes such as business overview, product segments and financial analysis. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global as well as regional migraine market.